Tenderwize
Retour à la recherche

Open house pharmaceutical rebate agreements for Alfacalcidol, ATC A11CC03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 461 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Alfacalcidol, ATC A11CC03

60/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

Agreements can be automatically superseded by future competitive rebate contracts, reducing potential volume.

Strict submission requirements: paper must be 2 copies, hand-signed; electronic requires qualified signature; both must...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive pharmaceutical rebate agreements (Rabattverträge) under §130a(8) SGB V
  • Active substance: Alfacalcidol, ATC code A11CC03
Afficher le résumé complet

Open house non-exclusive rebate agreement for the active ingredient Alfacalcidol (ATC A11CC03) by AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can join. No competitive selection; contract terms are fixed. Early contract start possible from 01.02.2026, with all contracts ending 31.01.2028. Final date for contract conclusion is 03.12.2027.

Risques

Agreements can be automatically superseded by future competitive rebate contracts, reducing potential volume.

Strict submission requirements: paper must be 2 copies, hand-signed; electronic requires qualified signature; both must...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible

Certifications

  • Documents must be in German or accompanied by a certified German translation

Administrative

  • Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria - all eligible companies can join.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house pharmaceutical rebate agreements for Alfacalcidol, ATC A11CC03

Non-exclusive rebate agreements for the active ingredient Alfacalcidol. Open to all qualified pharmaceutical companies. Contract duration 24 months. Submission monthly by the 3rd for next month start. No award criteria or competition.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria - all eligible companies can join.

Date limite

Deadline Dec 03, 2027

Détails de la procédure

Date de publication
14 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
829127-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30